William Martin, Ph.D.
Dr. Martin is the President of Lotus CRO and has served as the Chief Scientific Officer of the Evolution Research Group. Dr. Martin has worked in a variety of roles across the biopharmaceutical industry over the last 20 plus years, including time as a Research Coordinator, Study Monitor, Sub-Investigator and Medical Director. Most recently, Dr. Martin served as Senior Medical Director and Product Leader for Vivitrol® and was a Clinical Development Team Leader across several programs, including Lybalvi while at Alkermes. Prior to Alkermes, Dr. Martin worked in the Clinical Research and Precision Medicine group at Pfizer. Dr. Martin has experience across a broad range of CNS, metabolic and other therapeutic areas and has authored several publications related to his drug development work. In addition to his industry experience, Dr. Martin spent five years working as a clinical researcher at the University of Connecticut Metabolism Unit as well as at a private Urology and Men’s Health clinical trial center. Dr. Martin serves as a member of the Scientific Advisory Board (SAB) of Axial Biotherapeutics, a clinical stage biopharmaceutical company.
Neil Singla, MD
Chief Scientific Officer
Dr. Neil Singla, a board-certified anesthesiologist, is the founder and Chief Scientific Officer of Lotus Clinical Research. Since its inception in 2001, Dr. Singla has served in several roles within the organization including: Research Coordinator, Sub-Investigator, Principal Investigator, Coordinating Investigator, and Chief Scientific Officer.
In his capacity as CSO for Lotus Clinical Research, Dr. Singla has had the opportunity to interact frequently with the FDA’s Analgesics Division on behalf of clients and to play a significant role in guiding development strategies for dozens of putative analgesic agents. In the company’s 18-year history, Dr. Singla and Lotus Clinical Research have played a significant role in bringing several molecules to market.
Dr. Singla has published extensively and is a frequent lecturer for physicians, pharmaceutical companies, and medical research institutes throughout the country. He currently chairs the Analgesic Clinical Trials Shared/Special Interest Group at the International Association for the Study of Pain (IASP), chaired the Clinical Trials Shared Interest Group at the American Pain Society (APS) through 2019, chairs the annual Conference on Analgesic Clinical Trials, which aims to help experts advance best practices in analgesic drug development, as well as, serving on the Clinical Research Committee at Huntington Hospital.
The main focus of Dr. Singla’s academic endeavors has been to analyze and understand how the inherent variability in subjective endpoint analgesic clinical trials can be minimized. As a result, he has developed novel techniques for patient education designed to minimize variability, reduce placebo response, and increase effect size.
Sr. Vice President, Biometrics
Bill is a senior Biometrics leader with over 23 years of management experience in the pharmaceutical industry (biometrics and regulatory). Bill brings extensive expertise in data visualization, data operations (data acquisition, data management, data QC) to facilitate data collection, data mining, accuracy and integrity to support clinical trials. After working on the sponsor side for over 10 years, Bill went on to run CD3, a Biometrics firm, as President and CEO for over 10 years. Bill has B.S. degree in engineering from the University of Rhode Island and his M.S. degree in Management/ Finance from RPI.
Vice President, Clinical Operations
Amy Crary is a results-oriented clinical research professional with over 25 years of experience in CRO and pharmaceutical company settings. In her role as Vice President of Clinical Operations she manages the project management, clinical and regulatory teams ensuring successful delivery to our clients. Prior to joining Lotus she served in project delivery oversight roles at large and mid-sized CROs. She also served as Senior Director of Clinical Trials at a mid-sized pharmaceutical company specializing in pain management. She has experience in Phase I – IV trials in multiple therapeutic areas including acute and chronic pain in addition to other CNS indications. Amy has a B.S. Degree in Medical Technology and is a certified Project Management Professional.
Vice President, Quality Operations
Christopher Bowman has over 15 years of experience in clinical research spanning regulatory compliance, quality assurance, and clinical management of Phase I through Phase IV studies. Prior to joining Lotus, he held positions as the Director of Clinical Operations for a clinical and regulatory consulting firm and served as the Director of Quality Operations for a large Phase I-IV clinical trial center. Mr. Bowman has extensive knowledge in Federal Regulations and GCP/ICH guidance with over 12 years conducting GCP compliance audits including investigational sites, sponsors, CROs, clinical vendors, trial master files, IRBs, and FDA readiness visits both in the U.S. and abroad.